REGN vs RPRX: Regeneron Pharmaceuticals and Royalty Pharma Plc compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Regeneron Pharmaceuticals is the larger company, worth $68.5B, about 2.1 times Royalty Pharma Plc.
- Regeneron Pharmaceuticals grew revenue faster over the last year (+16.7% vs +16.5%).
- Royalty Pharma Plc keeps more of each dollar of revenue as operating profit (59.6% vs 24.7%).
- On earnings, Regeneron Pharmaceuticals is the cheaper stock (16.0x vs 29.5x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | REGN | RPRX |
|---|---|---|
| Market cap | $68.5B | $32.3B |
| Share price | $746.54 | $56.93 |
| Revenue (last fiscal year) | $14.3B | $2.4B |
| Free cash flow (last fiscal year) | $4.1B | — |
| Revenue growth, last year | +16.7% | +16.5% |
| Revenue growth per year, last 5 fiscal years | -2.8% | +1.0% |
| Operating margin | 24.7% | 59.6% |
| Net margin | 27.9% | 32.1% |
| Return on equity | 13.7% | 8.3% |
| P/E (trailing) | 16.0x | 29.5x |
| Price / free cash flow | 16.8x | 13.0x |
| EV / EBITDA | 12.4x | 19.1x |
| FCF growth the price implies | 2.7% | — |
| Dividend yield | 0.55% | 1.6% |
| Debt / equity | 0.32x | 1.03x |
| Fundamental grade | B | C |
| Superinvestors holding it | 7 | 3 |
| Insider purchases, last 12 months | 8 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Regeneron Pharmaceuticals
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $16.1B | $6.5B | 55.7% |
| 2022 | $12.2B | $4.4B | 38.9% |
| 2023 | $13.1B | $3.9B | 30.9% |
| 2024 | $14.2B | $3.7B | 28.1% |
| 2025 | $14.3B | $4.1B | 24.9% |
Royalty Pharma Plc
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $2.3B | — | 62.5% |
| 2022 | $2.2B | — | 13.7% |
| 2023 | $2.4B | — | 63.4% |
| 2024 | $2.3B | — | 57.1% |
| 2025 | $2.4B | — | 65.6% |
Where the revenue comes from
Regeneron Pharmaceuticals · by products, 2025
Collaboration revenue$7.3B51%
Net product sales$6.3B44%
Other revenue$703M5%
Royalty Pharma Plc · by products, 2025
Income from financial royalty assets$2.3B95%
Other royalty income and revenues$117M5%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open REGN in InvestinglyQuestions
Which is bigger, Regeneron Pharmaceuticals or Royalty Pharma Plc?
Regeneron Pharmaceuticals (REGN), at $68.5B against $32.3B.
Is REGN or RPRX cheaper?
By trailing P/E, Regeneron Pharmaceuticals (16.0x) is cheaper than Royalty Pharma Plc (29.5x). A lower multiple can also mean the market expects less growth.
Which grows faster, REGN or RPRX?
Regeneron Pharmaceuticals: revenue grew +16.7% over the last year, against +16.5%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.